Full Disclaimer
Condition:
All Conditions
Acute Disseminated Encephalomyelitis (ADEM)
Addison's Disease
Alopecia Areata
Ankylosing Spondylitis (AS)
Anti-NMDA Receptor Encephalitis
Antiphospholipid Syndrome
Celiac Disease
Cicatricial Pemphigoid
Crohn's Disease
Dermatitis Herpetiformis (DH)
Dermatomyositis
Giant Cell Arteritis (GCA)
Graves' Disease
Graves' Ophthalmopathy
Guillain-Barre Syndrome
IgA Nephropathy
Immune Thrombocytopenia (ITP)
Lupus
Membranous Nephropathy
Multiple Sclerosis
Myasthenia Gravis
Myositis
Polymyalgia Rheumatica
Psoriasis
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sjogren's Syndrome
Type 1 Diabetes Mellitus
Vitiligo
A phase 3 clinical trial found that ianalumab, a novel B-cell targeting agent, significantly extended the time patients with immune thromboc...
Read More — Ianalumab plus Eltrombopag Extends Time to Treatment Failure in Previously Treated Immune Thrombocytopenia: Phase 3 VAYHIT2 Trial »
New England Journal of Medicine · 2025
A major phase 3 clinical trial published in the New England Journal of Medicine found that atacicept, a dual BAFF/APRIL inhibitor, reduced p...
Read More — Atacicept Reduces Proteinuria by 46% in Phase 3 IgA Nephropathy Trial, ORIGIN 3 Study Shows »
New England Journal of Medicine · 2025
A phase 3 clinical trial published in the New England Journal of Medicine found that icotrokinra, the first oral peptide to selectively bloc...
Read More — First-in-Class Oral IL-23 Receptor Blocker Icotrokinra Achieves 65% Skin Clearance in Phase 3 Psoriasis Trial »
New England Journal of Medicine · 2025
A Cell Press review in Trends in Molecular Medicine surveys emerging therapies for anti-NMDA receptor encephalitis, including IL-6 inhibitor...
Read More — New Review Maps Future Treatment Directions for Anti-NMDA Receptor Encephalitis »
Trends in Molecular Medicine · 2025
A landmark Dutch randomized trial published in the New England Journal of Medicine has found that methotrexate, long used as a second-line t...
Read More — PREDMETH Trial: Methotrexate Noninferior to Prednisone as First-Line Therapy for Pulmonary Sarcoidosis »
New England Journal of Medicine · 2025
A 2025 review of the rapidly expanding pharmacological landscape for Graves' ophthalmopathy highlights how new biologics, including teprotum...
Read More — Novel Biologics Including FcRn Inhibitors and IGF-1R Blockers Transforming Treatment of Graves' Ophthalmopathy »
Frontiers in Immunology · 2025
New England Journal of Medicine · 2025
A bioprinted, off-the-shelf implantable cell therapy developed by Aspect Biosystems restored natural cortisol production in adrenalectomized...
Read More — Implantable Cell Therapy Restores Natural Cortisol Rhythms in Addison's Disease Animal Research »
2025
A 2025 randomized trial published in Clinical Rheumatology found that baricitinib, a JAK1/2 inhibitor already approved for rheumatoid arthri...
Read More — BASICS Trial: Baricitinib 4 mg Significantly Reduces Skin Fibrosis in Systemic Sclerosis »
Clinical Rheumatology · 2025
A phase 3 clinical trial found that inebilizumab, a CD19-targeting antibody that depletes B cells, significantly improved daily functioning...
Read More — Inebilizumab Significantly Improves Function in Generalized Myasthenia Gravis: Phase 3 MINT Trial »
New England Journal of Medicine · 2025
For the first time, a drug has shown a statistically significant ability to slow disability progression in people with nonrelapsing secondar...
Read More — Tolebrutinib Reduces Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis: Phase 3 HERCULES Trial »
New England Journal of Medicine · 2025
A large phase 3 clinical trial found that upadacitinib, an oral JAK inhibitor, helped significantly more patients with giant cell arteritis...
Read More — JAK Inhibitor Upadacitinib Achieves Superior Sustained Remission in Giant Cell Arteritis Phase 3 Trial »
New England Journal of Medicine · 2025
